Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilengitide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.78 |
| ▸ | ITGAV known ✓ | P06756 | 18/20 | 0.78 |
| ▸ | ITGB5 known ✓ | P18084 | 8/20 | 0.78 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.78 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.78 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.68 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.65 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilengitide SCHEMBL19534260 | 1.00 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL26970603 | 1.00 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL29403053 | 0.99 | ITGB3 (0.77) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL31098146 | 0.96 | ITGB3 (0.72) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16883990 | 0.89 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL22193974 | 0.89 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16884024 | 0.89 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL31294830 | 0.88 | ITGB3 (0.80) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL22193980 | 0.87 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cyclorgdfv SCHEMBL30636069 | 0.87 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9649 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12601743-B2 | Methods for treating drug resistant cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-14 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-20260042843-A1 | METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS | Temple Therapeutics BV (NL) | 2026-02-12 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-20050239692-A1 | Aqueous preparation containing oligopeptides and etherified cyclodextrin | MERCK PATENT GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | claimed |
| CN-1662250-A | Aqueous preparation containing oligopeptides and etherified cyclodextrin | MERCK PATENT GMBH (DE) | 2005-08-31 | — | — | CN | claimed |
| WO-2005048942-A2 | COMBINATION THERAPY COMPRISING A COX-2 INHIBITOR AND AN ANTINEOPLASTIC AGENT | PHARMACIA CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050074497-A1 | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases | DIRECTCONTACT LLC | 2005-04-07 | — | — | US | claimed |
| EP-1515740-A1 | AQUEOUS PREPARATION CONTAINING OLIGOPEPTIDES AND ETHERIFIED CYCLODEXTRIN | MERCK PATENT GmbH (DE) | 2005-03-23 | — | — | EP | claimed |
| EP-1435967-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2004000344-A1 | AQUEOUS PREPARATION CONTAINING OLIGOPEPTIDES AND ETHERIFIED CYCLODEXTRIN | MERCK PATENT GMBH (DE) | 2003-12-31 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003032961-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | PHARMACIA ITALIA SPA (IT) | 2003-04-24 | — | — | WO | claimed |